Pharma execs shower Cassidy with campaign cash; Eli Lilly's weight-loss drug succeeds in second study

Taking stock of the drug industry, from the lab to the medicine chest

April 27, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

J. Scott Applewhite/AP STAT+ | Pharma executives shower Bill Cassidy with campaign cash Sen. Bill Cassidy's perch as the top Republican on the Senate health committee attracted campaign cash from pharma execs. By Rachel Cohrs and Sarah Owermohle STAT+ | Eli Lilly's Mounjaro succeeds in second weight loss study, paving way for FDA review Wall Street analysts expect the results to pave the way for approval of Mounjaro by the Food and Drug Administration. By Matthew Herper STAT+ | Health insurance CEOs set another record for pay in 2022 The CEOs of seven major health insurers together made more than $335 million in 2022. Molina's CEO brought in $181 million alone. By Bob Herman Ruby Wallau for STAT STAT+ | FDA approves Seres microbiome drug, as field advances Seres Therapeutics' drug, called Vowst, works by introducing good bacteria back into the digestive system. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser